Applications of Cbz-D-Phenylalaninol in Industrial Manufacturing

Cbz-D-Phenylalaninol is an established synthetic intermediate manufactured to support regulated industrial sectors. The following application scenarios detail real downstream uses within pharmaceutical and fine chemical manufacturing, based on our expertise in raw material production for controlled, high-purity markets.

1. Peptide Synthesis for Active Pharmaceutical Ingredients (APIs)

Chemical manufacturers employ Cbz-D-Phenylalaninol as a protected chiral building block during stepwise solid-phase or solution-phase peptide synthesis, particularly for APIs targeting central nervous system and metabolic disorders. Its Cbz (carbobenzyloxy) guarding group allows selective deprotection during elongation without racemization. Batch records track input, process timing, and removal to meet stringent pharmaceutical standards. Researchers specify D-configuration to ensure stereochemical integrity in enantiopure peptides destined for clinical development.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• European Pharmacopoeia (Ph. Eur.) monographs for peptide API synthesis
• U.S. FDA 21 CFR Part 210/211 (cGMP for Finished Pharmaceuticals)
• Japanese Pharmacopoeia (JP) if supplied to Japan

Typical usage ratio

• Usage typically ranges from 1 to 1.2 molar equivalents relative to the required D-phenylalanine content per peptide chain.
• Slight excess helps drive reaction to completion; ratio adjusted based on peptide sequence complexity and coupling efficiency.

Downstream process integration

• Raw material introduced during protected amino alcohol coupling in peptide elongation cycles.
• Chemical deprotection stages selectively remove Cbz under mild hydrogenation following backbone assembly.
• Product enters purification, lyophilization, and QC stages aligned to pharmaceutical SOPs.

Final product types

• Custom oligopeptides with D-amino acid incorporation for drug candidates
• Clinical-grade peptide APIs with specified D-residue content
• Reference standards for enantiomeric purity controls

2. Chiral Auxiliary in Pharmaceutical Intermediate Manufacturing

Chiral synthesis platforms utilize Cbz-D-Phenylalaninol as a temporary stereocontrolling auxiliary. It guides enantioselective addition reactions, facilitating the assembly of advanced pharmaceutical intermediates. After reaction completion, processors remove both the Cbz group and the auxiliary in controlled steps to generate complex, optically pure molecules required by the patented drug synthesis routes. GMP batch tracking ensures full traceability at every stage.

Industry compliance standards

• ICH Q11 Development and Manufacture of Drug Substances
• ISO 9001:2015 Quality Management Systems (relevant for controlled documentation)
• REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) compliance for EU export
• Chemical safety assessment as per CLP Regulation (EC No 1272/2008)

Typical usage ratio

• Applied at 1.0–1.5 equivalents per substrate molecule, dependent on desired stereochemical outcome and downstream hydrolysis efficiency.
• Excess is minimized to reduce auxiliary recovery and separation burden.

Downstream process integration

• Employed in key chiral step using either solution-phase or continuous flow processing.
• Auxiliary removed post-reaction by acid or hydrogenation in dedicated reactor vessels.
• Intermediates further derivatized or cyclized as required by patented synthetic route.

Final product types

• Chiral alcohol intermediates for antihypertensive agents
• Benzyl-protected secondary amine derivatives
• Advanced aldehyde or acid API precursors

3. Protected Amino Alcohol for Small Molecule API Development

R&D and pilot-scale pharmaceutical plants value Cbz-D-Phenylalaninol for assembling protected intermediates used in novel small molecule synthesis. The Cbz group shields amine functions through oxidation, coupling, or ring formation steps, crucial for designing CNS, oncology, or antidiabetic agent candidates. Labs integrate this intermediate to streamline multi-step routes while retaining full analytical traceability from raw input to final isolated compound.

Industry compliance standards

• U.S. Pharmacopeia (USP) guidance for intermediate handling
• FDA cGMP regulations for investigational drug substances (IND-enabling chemistry)
• EMA guideline on the chemistry of active substances (EMA/CHMP/QWP/130/96 Rev1)
• ICH Q9 Quality Risk Management in process chemistry

Typical usage ratio

• Common loading is 1.0 molar equivalent per core structure.
• Adjusted based on the planned synthetic route and stepwise isolation requirements—higher ratios for difficult couplings or when scaling up.

Downstream process integration

• Charged to reactors for stepwise reduction, cyclization, or condensation as a protected amino alcohol.
• Cbz group removed after final transformation prior to formulation or solid-phase separation.
• QC teams use NMR and mass spectrometry to confirm integrity.

Final product types

• Custom small molecule reference standards (containing D-phenylalaninol motif)
• Pharmaceutical building blocks for neurological and metabolic disease indications
• Advanced intermediates for authorized generic or branded drugs

4. Specialty Fine Chemicals for Chiral Ligand Synthesis

Chemical companies supplying catalysts and fine chemicals formulate chiral ligands based on D-phenylalaninol architecture, frequently protected as Cbz derivatives to withstand complex organometallic environments. These chiral ligands serve as key enabling agents in asymmetric hydrogenation, Diels–Alder, or cross-coupling reactions across agrochemical, pharmaceutical, and flavor industries. The protected group ensures ligand stability through metal complexation and downstream transformation, supporting higher catalytic selectivity and product purity.

Industry compliance standards

• ISO 9001:2015 for fine chemical production systems
• REACH registration for chiral intermediates supplied to EU customers
• GHS-compliant safety data sheets and labeling practices
• Material traceability as per customer-specific QA protocols

Typical usage ratio

• Ligand synthesis generally uses 1.0 molar equivalent relative to the core framework or activated base structure.
• Processors may scale to a slight excess (1.1 equivalents) to ensure complete conversion and batch homogeneity.

Downstream process integration

• Preparation begins with nucleophilic addition or substitution using the protected amino alcohol as a chiral backbone.
• Cbz protection enables direct incorporation into catalytic ligand frameworks prior to metal complexing.
• Chemical deprotection occurs post-synthesis, or in situ during catalyst activation under controlled conditions.

Final product types

• Custom chiral ligands for asymmetric synthesis platforms
• Specialty catalyst precursors for fine chemical transformations
• Analytical reference ligands for enantioselectivity studies

5. Reference Material Production for Analytical Laboratories

Accredited analytical standards manufacturers utilize Cbz-D-Phenylalaninol to provide highly characterized reference materials. These substances support USP, Ph. Eur., and ISO-accredited labs in validating enantiomeric resolution, calibration of chiral chromatography columns, and performance assessment of purity assays. Full traceability with supporting NMR, HPLC, and MS data underpins the distributed reference materials, meeting regulatory and scientific reproducibility demands.

Industry compliance standards

• ISO/IEC 17025:2017 for testing and calibration laboratories
• USP Reference Standards General Notices
• Ph. Eur. Reference Substances requirements
• GLP (Good Laboratory Practice) for analytical reference production

Typical usage ratio

• Material prepared at analytical concentrations from 0.1% up to 10% w/w, according to validation requirements of target assay.
• Exact quantity and grade specified per assay protocol and regulatory method guidelines.

Downstream process integration

• Cbz-D-Phenylalaninol weighed and dissolved during formulation of calibration mixes.
• QC conducted using chiral HPLC/UPLC and mass spectrometric characterization.
• Portions dispensed into certified vials for distribution to laboratories.

Final product types

• Certified reference materials (CRMs) for enantiopure compound analysis
• Analytical standards for chiral chromatography calibration
• Proficiency testing samples for accredited testing facilities